These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 20634178)

  • 41. Papillary thyroid cancer: medical management and follow-up.
    Kloos RT
    Curr Treat Options Oncol; 2005 Jul; 6(4):323-38. PubMed ID: 15967085
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pre-Ablation rhTSH-Stimulated F-18 FDG PET/CT Changes Patient Management in Increased-Risk Thyroid Cancer.
    Rendl G; Rettenbacher L; Schweighofer-Zwink G; Hehenwarter L; Pirich C
    Horm Metab Res; 2020 Mar; 52(3):158-167. PubMed ID: 32215887
    [TBL] [Abstract][Full Text] [Related]  

  • 43. RAI thyroid bed uptake after total thyroidectomy: A novel SPECT-CT anatomic classification system.
    Zeuren R; Biagini A; Grewal RK; Randolph GW; Kamani D; Sabra MM; Shaha AR; Tuttle RM
    Laryngoscope; 2015 Oct; 125(10):2417-24. PubMed ID: 25891354
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.
    Dehbi HM; Mallick U; Wadsley J; Newbold K; Harmer C; Hackshaw A
    Lancet Diabetes Endocrinol; 2019 Jan; 7(1):44-51. PubMed ID: 30501974
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Insular thyroid carcinoma in adolescents: a potentially lethal endocrine malignancy.
    Hassoun AA; Hay ID; Goellner JR; Zimmerman D
    Cancer; 1997 Mar; 79(5):1044-8. PubMed ID: 9041169
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Improving postoperative recurrence rates for carcinoma of the thyroid gland.
    McHenry C; Jarosz H; Lawrence AM; Paloyan E
    Surg Gynecol Obstet; 1989 Nov; 169(5):429-34. PubMed ID: 2814754
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fine needle aspiration of poorly differentiated oxyphilic (Hürthle cell) thyroid carcinoma: a case report.
    Ghofrani M; Sosa JA; Ocal IT; Angeletti C
    Acta Cytol; 2006; 50(5):560-2. PubMed ID: 17017447
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical utility of 18F-FDG PET/CT concurrent with 131I therapy in intermediate-to-high-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients.
    Lee JW; Lee SM; Lee DH; Kim YJ
    J Nucl Med; 2013 Aug; 54(8):1230-6. PubMed ID: 23813775
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical features and prognostic factors for survival in patients with poorly differentiated thyroid carcinoma and comparison to the patients with the aggressive variants of papillary thyroid carcinoma.
    Jung TS; Kim TY; Kim KW; Oh YL; Park DJ; Cho BY; Shong YK; Kim WB; Park YJ; Jung JH; Chung JH
    Endocr J; 2007 Apr; 54(2):265-74. PubMed ID: 17379963
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.
    Tuttle RM; Lopez N; Leboeuf R; Minkowitz SM; Grewal R; Brokhin M; Omry G; Larson S
    Thyroid; 2010 Mar; 20(3):257-63. PubMed ID: 20187781
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels.
    Muros MA; Llamas-Elvira JM; Ramírez-Navarro A; Gómez MJ; Rodríguez-Fernández A; Muros T; López de la Torre M; Becerra A; Carreras JL
    Am J Surg; 2000 Jun; 179(6):457-61. PubMed ID: 11004330
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of early 18F-FDG PET/CT in therapeutic management and ongoing risk stratification of high/intermediate-risk thyroid carcinoma.
    Triviño Ibáñez EM; Muros MA; Torres Vela E; Llamas Elvira JM
    Endocrine; 2016 Mar; 51(3):490-8. PubMed ID: 26224589
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of imaging tests after primary treatment of thyroid cancer in the United States: population based retrospective cohort study evaluating death and recurrence.
    Banerjee M; Wiebel JL; Guo C; Gay B; Haymart MR
    BMJ; 2016 Jul; 354():i3839. PubMed ID: 27443325
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Approach to the patient with a positive serum thyroglobulin and a negative radioiodine scan after initial therapy for differentiated thyroid cancer.
    Kloos RT
    J Clin Endocrinol Metab; 2008 May; 93(5):1519-25. PubMed ID: 18463349
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High CEA levels in a case of resected colorectal cancer: delayed diagnosis of metachronous medullary thyroid cancer.
    Chen SW; Chen YK
    World J Surg Oncol; 2017 Dec; 15(1):230. PubMed ID: 29284496
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of suspected recurrent papillary thyroid carcinoma with [18F]fluorodeoxyglucose positron emission tomography.
    Jadvar H; McDougall IR; Segall GM
    Nucl Med Commun; 1998 Jun; 19(6):547-54. PubMed ID: 10234658
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
    Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
    Wang W; Macapinlac H; Larson SM; Yeh SD; Akhurst T; Finn RD; Rosai J; Robbins RJ
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence.
    Rosário PW; Calsolari MR
    Thyroid; 2014 May; 24(5):826-31. PubMed ID: 24283207
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Follicular thyroid carcinoma: From diagnosis to treatment.
    Lin JD; Chao TC
    Endocr J; 2006 Aug; 53(4):441-8. PubMed ID: 16807500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.